|
1
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
2
|
Jefferies S and Foulkes WD: Genetic
mechanisms in squamous cell carcinoma of the head and neck. Oral
Oncol. 37:115–126. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herskovic A, Martz K, al-Sarraf M,
Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L
and Emami B: Combined chemotherapy and radiotherapy compared with
radiotherapy alone in patients with cancer of the esophagus. N Engl
J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar
|
|
5
|
Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD,
Choi YH and Kim GY: Beta-lapachone (LAPA) decreases cell viability
and telomerase activity in leukemia cells: Suppression of
telomerase activity by LAPA. J Med Food. 13:481–488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferreira SB, Salomão K, de Carvalho da
Silva F, Pinto AV, Kaiser CR, Pinto AC, Ferreira VF and de Castro
SL: Synthesis and anti-Trypanosoma cruzi activity of β-lapachone
analogues. Eur J Med Chem. 46:3071–3077. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Almeida ER, da Silva Filho AA, dos
Santos ER and Lopes CA: Antiinflammatory action of lapachol. J
Ethnopharmacol. 29:239–241. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tzeng HP, Ho FM, Chao KF, Kuo ML,
Lin-Shiau SY and Liu SH: beta-Lapachone reduces endotoxin-induced
macrophage activation and lung edema and mortality. Am J Respir
Crit Care Med. 168:85–91. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guiraud P, Steiman R, Campos-Takaki GM,
Seigle-Murandi F and Simeon de Buochberg M: Comparison of
antibacterial and antifungal activities of lapachol and
beta-lapachone. Planta Med. 60:373–374. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS
and Pardee AB: Three inhibitors of type 1 human immunodeficiency
virus long terminal repeat-directed gene expression and virus
replication. Proc Natl Acad Sci USA. 90:1839–1842. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kung HN, Yang MJ, Chang CF, Chau YP and Lu
KS: In vitro and in vivo wound healing-promoting activities of
beta-lapachone. Am J Physiol Cell Physiol. 295:C931–C943. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Planchon SM, Wuerzberger S, Frydman B,
Witiak DT, Hutson P, Church DR, Wilding G and Boothman DA:
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia
(HL-60) and human prostate cancer cells: A p53-independent
response. Cancer Res. 55:3706–3711. 1995.PubMed/NCBI
|
|
13
|
Planchon SM, Pink JJ, Tagliarino C,
Bornmann WG, Varnes ME and Boothman DA: beta-Lapachone-induced
apoptosis in human prostate cancer cells: Involvement of NQO1/xip3.
Exp Cell Res. 267:95–106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li CJ, Averboukh L and Pardee AB:
beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode
of action different from camptothecin. J Biol Chem.
268:22463–22468. 1993.PubMed/NCBI
|
|
15
|
Krishnan P and Bastow KF: Novel mechanism
of cellular DNA topoisomerase II inhibition by the
pyranonaphthoquinone derivatives alpha-lapachone and
beta-lapachone. Cancer Chemother Pharmacol. 47:187–198. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JH, Cheong J, Park YM and Choi YH:
Down-regulation of cyclooxygenase-2 and telomerase activity by
beta-lapachone in human prostate carcinoma cells. Pharmacol Res.
51:553–560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wierstra I: Sp1: emerging roles - beyond
constitutive activation of TATA-less housekeeping genes. Biochem
Biophys Res Commun. 372:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and krüppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao
J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression
level of insulin-like growth factor I receptor is associated with
increased expression of transcription factor Sp1 and regional lymph
node metastasis of human gastric cancer. Clin Exp Metastasis.
21:755–764. 2004. View Article : Google Scholar
|
|
20
|
Chae JI, Jeon YJ and Shim JH:
Downregulation of Sp1 is involved in honokiol-induced cell cycle
arrest and apoptosis in human malignant pleural mesothelioma cells.
Oncol Rep. 29:2318–2324. 2013.PubMed/NCBI
|
|
21
|
Kim DW, Ko SM, Jeon YJ, Noh YW, Choi NJ,
Cho SD, Moon HS, Cho YS, Shin JC, Park SM, et al:
Anti-proliferative effect of honokiol in oral squamous cancer
through the regulation of specificity protein 1. Int J Oncol.
43:1103–1110. 2013.PubMed/NCBI
|
|
22
|
Mann J: Natural products in cancer
chemotherapy: Past, present and future. Nat Rev Cancer. 2:143–148.
2002. View
Article : Google Scholar
|
|
23
|
Wilson RM and Danishefsky SJ: Small
molecule natural products in the discovery of therapeutic agents:
The synthesis connection. J Org Chem. 71:8329–8351. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jackson JK, Higo T, Hunter WL and Burt HM:
Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res.
57:126–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tudan C, Jackson JK, Higo TT and Burt HM:
The effect of inhibiting topoisomerase I and II on the
anti-apoptotic response associated with pro-inflammatory crystals
of calcium pyrophosphate dihydrate in human neutrophils. Inflamm
Res. 52:8–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pink JJ, Wuerzberger-Davis S, Tagliarino
C, Planchon SM, Yang X, Froelich CJ and Boothman DA: Activation of
a cysteine protease in MCF-7 and T47D breast cancer cells during
beta-lapachone-mediated apoptosis. Exp Cell Res. 255:144–155. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wuerzberger SM, Pink JJ, Planchon SM,
Byers KL, Bornmann WG and Boothman DA: Induction of apoptosis in
MCF-7:WS8 breast cancer cells by beta-lapachone. Cancer Res.
58:1876–1885. 1998.PubMed/NCBI
|
|
28
|
Choi YH, Kang HS and Yoo MA: Suppression
of human prostate cancer cell growth by beta-lapachone via
down-regulation of pRB phosphorylation and induction of Cdk
inhibitor p21(WAF1/CIP1). J Biochem Mol Biol. 36:223–229. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dong GZ, Oh ET, Lee H, Park MT, Song CW
and Park HJ: Beta-lapachone suppresses radiation-induced activation
of nuclear factor-kappaB. Exp Mol Med. 42:327–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC,
Chang WC and Hung JJ: Sp1 expression regulates lung tumor
progression. Oncogene. 31:3973–3988. 2012. View Article : Google Scholar :
|
|
33
|
Kavurma MM and Khachigian LM: Sp1 inhibits
proliferation and induces apoptosis in vascular smooth muscle cells
by repressing p21WAF1/Cip1 transcription and cyclin
D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem.
278:32537–32543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu R, Zhang P, Huang J, Ge S, Lu J and
Qian G: Sp1 and Sp3 regulate basal transcription of the survivin
gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sankpal UT, Goodison S, Abdelrahim M and
Basha R: Targeting Sp1 transcription factors in prostate cancer
therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chae JI, Jeon YJ and Shim JH:
Anti-proliferative properties of kahweol in oral squamous cancer
through the regulation specificity protein 1. Phytother Res.
28:1879–1886. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Murray AW: Recycling the cell cycle:
Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ewen ME and Lamb J: The activities of
cyclin D1 that drive tumorigenesis. Trends Mol Med. 10:158–162.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weinstein IB: Relevance of cyclin D1 and
other molecular markers to cancer chemoprevention. J Cell Biochem.
(Suppl 25): S23–S28. 1996. View Article : Google Scholar
|
|
42
|
Xu Q, Liu M, Xu N and Zhu H: Variation in
Sp1 binding sites correlates with expression of survivin in breast
cancer. Mol Med Rep. 10:1395–1399. 2014.PubMed/NCBI
|
